Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.
about
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse modelThe evolution of poxvirus vaccinesMatrix and backstage: cellular substrates for viral vaccinesCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxPoxvirus tropismA survey of host range genes in poxvirus genomesEPIPOX: Immunoinformatic Characterization of the Shared T-Cell Epitome between Variola Virus and Related Pathogenic OrthopoxvirusesPoxviruses and the evolution of host range and virulenceA Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsA pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizationsModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesViral vector-based influenza vaccines.Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesInduction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).Orf: an update on current research and future perspectives.Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine modelEfficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceRole of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVPoxvirus-induced immunostimulating effects on porcine leukocytes.Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccinationEvaluation of smallpox vaccines using variola neutralization.Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.The influence of delivery vectors on HIV vaccine efficacyIntroduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraEscape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in miceDeletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensIdentification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.
P2860
Q24276422-CB39FA2C-839A-49AE-BF03-2BD24FC23452Q26995905-EC54C07C-C9D8-41AF-A4C1-326FE0EF7F0FQ27025941-3EEABC3F-923C-4D60-AE48-69AE785A9F34Q27346933-21B795A6-55AD-4DB0-88D6-816A99C0CD84Q28237434-FBA0CA1E-AE5D-49F6-93F5-3741658A8778Q28389388-58260904-9269-4500-8AD6-E9E09828FDD4Q28607584-60BE97A2-FDAB-44F8-99D0-212B82F827D0Q28658130-B188827D-8463-4627-9880-69DB99D58275Q28742450-8E591368-7D3D-4F8C-A413-DA62710FBF28Q28749671-9EDD41C1-7755-40F1-8835-E65226ED21CBQ30209342-3E443A15-D1E0-4BE4-883D-D79E10D446C8Q30390938-B2CAED8F-F364-4DBE-B9E7-E1C7749A278FQ33187731-7C7EC14A-8F6B-4179-9624-83377EB91574Q33328336-AC8A4881-B51D-42BF-B2A2-CE068E737FBBQ33440600-29E53001-2516-43F5-A540-2380D30BB07FQ33471448-D7ECBFFD-9D8F-4DA9-B663-52F5F52305A4Q33500628-3D8AF238-665A-4AE8-AC18-05D4CE4429C5Q33602820-12F6020A-534D-4B3E-B292-5221087C0D82Q33632203-A4538F23-C2D0-413E-B97A-DB3E1A0D2458Q33635050-9631E02C-8CD0-4813-9C78-3A9C84038E92Q33696283-E206D743-4BF6-4819-97D9-C593D69BEB2CQ33780579-4AE24BCE-FC47-4C9D-97F1-8DE7D2B044E3Q33784928-2F0E57DC-B765-4125-9667-AAE8951BB102Q33799497-696F1CE4-9F11-401B-9F5A-04BE50905D01Q33800033-8168BB0E-719E-498F-90A3-9BD0A3C08F5BQ33810581-063693E1-83EB-421E-93F1-F8DDB206DB05Q33826983-2A588DCC-F9DF-442E-AACC-E9015AC72551Q33834543-1EAEB544-187B-496E-B747-BF8698E1F9FDQ33851802-B1BAF069-0EFE-4D73-A50F-508D82B72A55Q33920540-F0B0B407-301B-4EE8-AA8E-330BEA9A1CF7Q33930815-5FC9BA00-951E-4808-8AA7-CE9DE22C8DC3Q34077543-5564DEA1-0C56-48A4-A783-0253DEAC791BQ34120696-31510E19-45F1-4142-B7F0-74928F319F94Q34343169-6B4A1F57-4CD8-48CA-B42D-63A490273DC4Q34356817-0F56937F-2BCC-41F2-8251-098C6E4F4C00Q34428899-4BD3C388-9DCA-4337-A6B5-727B12786008Q34465228-EC9D028B-1D50-49E7-80C5-AB8050227A96Q34467405-62AEF21F-E02E-4742-8A2C-0B5C5EF6BCD1Q34470311-FB25AFB8-B53F-4260-B266-8A2079CDB969Q34471356-48EA899E-0673-480A-872F-58221B18B94F
P2860
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Mapping of deletions in the ge ...... their influence on virulence.
@en
type
label
Mapping of deletions in the ge ...... their influence on virulence.
@en
prefLabel
Mapping of deletions in the ge ...... their influence on virulence.
@en
P1476
Mapping of deletions in the ge ...... their influence on virulence.
@en
P304
P356
10.1099/0022-1317-72-5-1031
P407
P478
72 ( Pt 5)
P50
P577
1991-05-01T00:00:00Z